Product
Crizanlizuamb
1 clinical trial
1 indication
Indication
Sickle Cell DiseaseClinical trial
A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)Status: Completed, Estimated PCD: 2023-03-20